Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
about
Uricosuric medications for chronic goutAllopurinol for chronic goutProbenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin2011 recommendations for the diagnosis and management of gout and hyperuricemia.Allopurinol reduces antigen-specific and polyclonal activation of human T cells.The pharmacokinetics of oxypurinol in people with gout.Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients.Predicting allopurinol response in patients with goutGout and its comorbidities: implications for therapy.How do taste cells lacking synapses mediate neurotransmission? CALHM1, a voltage-gated ATP channel.Pharmacokinetics considerations for gout treatments.Urate-lowering therapy: current options and future prospects for elderly patients with gout.Assessment of genetic polymorphisms associated with hyperuricemia or gout in the Hmong.Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease.Individualising the dose of allopurinol in patients with gout.Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers
P2860
Q24187988-4481149F-9888-48B9-B5DF-92C181C194B6Q24193107-FC10CB2B-8A1E-4CE8-841C-C0F49C57C8ACQ28744318-8C6E95D0-C69F-47C4-B0BE-45D3E274CEC5Q34250995-75859864-6C8E-4E8D-AC81-9AC82A207C0AQ36250232-0E3D0A35-A5FE-42BE-BA06-D441871036ACQ36336035-161AAE52-8AB5-494B-A51F-62F378A154FAQ36633418-0FEA80E8-AC7E-455F-B76A-7F797BDB9624Q36802064-618E1B32-B40F-45D5-A057-945C55ECA2B6Q38040777-31A16400-17D8-40AD-92C8-81330A67B2F8Q38150798-E23ECB50-2223-4E98-9C3C-E626C9F3C163Q38210284-8D86BA25-A454-436F-B497-4245B50A0F3EQ38254304-78B33BE3-147D-403E-90BF-F9493D02E932Q41209052-72AA5155-BA5F-450B-BF05-61E6C2263825Q43230369-F035C1AA-2779-4658-9552-9F68D089A45EQ48266996-ABB9140E-FF23-41D6-87BE-E52CC4A912A1Q57415270-10B14D67-F133-431F-818A-536F3471B373
P2860
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pharmacokinetic and pharmacody ...... robenecid in healthy subjects.
@ast
Pharmacokinetic and pharmacody ...... robenecid in healthy subjects.
@en
Pharmacokinetic and pharmacody ...... robenecid in healthy subjects.
@nl
type
label
Pharmacokinetic and pharmacody ...... robenecid in healthy subjects.
@ast
Pharmacokinetic and pharmacody ...... robenecid in healthy subjects.
@en
Pharmacokinetic and pharmacody ...... robenecid in healthy subjects.
@nl
prefLabel
Pharmacokinetic and pharmacody ...... robenecid in healthy subjects.
@ast
Pharmacokinetic and pharmacody ...... robenecid in healthy subjects.
@en
Pharmacokinetic and pharmacody ...... robenecid in healthy subjects.
@nl
P2093
P1476
Pharmacokinetic and pharmacody ...... robenecid in healthy subjects.
@en
P2093
Garry G Graham
Kenneth M Williams
Sophie L Stocker
P2860
P304
P356
10.2165/00003088-200847020-00004
P577
2008-01-01T00:00:00Z
P6179
1053549676